Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

By D. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria, J. Prausová, G. Scagliotti, H. Sleeboom, A. Spencer, S. Vadhan-Raj and 8 more. Journal of Clinical Oncology, 2011

1,157 citations recorded by the source corpus.

Subfields: Nephrology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/44ac3df8c24138e9685ebf24d6803125f0666cda

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. C. Porta
2. Charles Swanton
3. K. Kerr
4. M. Hellmann

Citations in the corpus

• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “The receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor denosumab has been shown in a randomised trial to extend the time to first SRE by 4.3 months and was non-inferior to zoledronic acid [65].”
• Renal cell carcinoma (2017, background): “In widespread mRCC bone metastasis, bisphosphonate therapy with zoledronic acid has been shown to significantly reduce skeletal related events (SREs) in patients and increase time to first SRE [64].”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “The receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor denosumab has been shown in a randomised trial to extend the time to first SRE by 4.3 months and was non-inferior to zoledronic acid [65].”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Denosumab shows a trend towards superiority to zoledronic acid in lung cancer in terms of SRE prevention [II, B] [317].”